Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 783 |
| Supportive Care | 21 |
| Prevention | 10 |
| Basic Science | 6 |
| Other | 3 |
| Diagnostic | 1 |
| Health Services Research | 1 |
| NA | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 913 |
| interventional | 826 |
| Observational | 76 |
| Registry | 11 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 441 |
| Biological | 69 |
| Biological|Drug | 62 |
| Drug|Other | 48 |
| Biological|Drug|Other | 36 |
| Biological|Drug|Procedure|Radiation | 18 |
| Drug|Procedure | 14 |
| Biological|Other | 13 |
| Drug|Other|Procedure|Radiation | 13 |
| Procedure | 11 |
| Biological|Drug|Other|Procedure|Radiation | 10 |
| Drug|Procedure|Radiation | 9 |
| Drug|placebo | 8 |
| Biological|Drug|Radiation | 6 |
| Biological|Other|Procedure | 5 |
| Combination Product | 5 |
| Drug|Genetic | 4 |
| Drug|Radiation | 4 |
| Other | 4 |
| Biological|Drug|Genetic|Other | 3 |
| Biological|Drug|Other|Procedure | 3 |
| Biological|Drug|Procedure | 3 |
| Biological|Procedure | 3 |
| Dietary Supplement|Other | 3 |
| Drug|Other|Procedure | 3 |
| Biological|Drug|Genetic|Other|Procedure | 2 |
| Biological|Other|placebo | 2 |
| Drug|Genetic|Other | 2 |
| Other|Procedure | 2 |
| Behavioral | 1 |
| Behavioral|Dietary Supplement|Other | 1 |
| Biological|Device | 1 |
| Biological|Device|Drug|Procedure|Radiation | 1 |
| Biological|Device|Drug|Radiation | 1 |
| Biological|Dietary Supplement|placebo | 1 |
| Biological|Drug|Other|Radiation | 1 |
| Biological|Drug|placebo | 1 |
| Biological|Genetic|Other | 1 |
| Biological|Genetic|Other|Procedure | 1 |
| Biological|Procedure|Radiation | 1 |
| Device | 1 |
| Device|Drug | 1 |
| Device|Drug|Procedure|Radiation | 1 |
| Dietary Supplement | 1 |
| Dietary Supplement|Drug|Other | 1 |
| Dietary Supplement|placebo | 1 |
| Drug|Genetic|Procedure|Radiation | 1 |
| Drug|placebo|Procedure | 1 |
| Genetic | 1 |
| Country | Study_Count |
|---|---|
| United States | 519 |
| China | 29 |
| Germany | 23 |
| NA | 13 |
| France | 12 |
| United Kingdom | 12 |
| Canada | 9 |
| Italy | 9 |
| United States|Canada | 9 |
| Japan | 8 |
| Austria | 7 |
| Sweden | 7 |
| Spain | 6 |
| United States|Australia | 6 |
| United States|Italy | 6 |
| United States|Germany|Italy | 5 |
| Austria|Germany | 4 |
| United States|Germany | 4 |
| United States|United Kingdom | 4 |
| Korea, Republic of | 3 |
| Austria|France|Germany | 2 |
| Denmark | 2 |
| Germany|Austria | 2 |
| Lithuania | 2 |
| Spain|United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|France|Germany|Hong Kong|Italy|Mexico|Netherlands|New Zealand|Romania|Russian Federation|Slovakia|Switzerland|Thailand|United Kingdom | 2 |
| Switzerland | 2 |
| United States|Australia|Austria|Belgium|France|Germany|Hungary|Italy|New Zealand|Spain|United Kingdom | 2 |
| United States|Australia|Belgium|Canada|China|Czechia|Ireland|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Turkey|Ukraine|United Kingdom | 2 |
| United States|Australia|France|Poland | 2 |
| United States|Denmark|Germany | 2 |
| United States|Italy|United Kingdom | 2 |
| United States|Switzerland | 2 |
| Argentina|Australia|Brazil|Canada|Chile|Croatia|Czechia|France|Germany|Greece|Italy|Mexico|New Zealand|Poland|Portugal|Russian Federation|Slovakia|Spain|Turkey | 1 |
| Argentina|Australia|Bulgaria|Hong Kong|Hungary|Mexico|New Zealand|Poland|Russian Federation|Taiwan | 1 |
| Argentina|Belgium|Bosnia and Herzegovina|Brazil|Canada|Egypt|Estonia|Finland|France|Germany|Greece|Ireland|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Mexico|North Macedonia|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Thailand|Turkey | 1 |
| Argentina|Croatia|Greece|Ireland|Italy|New Zealand|Russian Federation|United Kingdom | 1 |
| Argentina|Venezuela | 1 |
| Australia | 1 |
| Australia|Austria|Belgium|Czech Republic|Denmark|France|Germany|Israel|Italy|New Zealand|Spain | 1 |
| Australia|China|New Zealand|Taiwan | 1 |
| Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom | 1 |
| Australia|Poland | 1 |
| Austria|Belgium|Bulgaria|Czechia|France|Germany|Hungary|Ireland|Israel|Italy|Poland|Russian Federation|Singapore|Slovakia|Sweden|Ukraine|United Kingdom | 1 |
| Austria|Belgium|France|Italy | 1 |
| Austria|Brazil|United States|Argentina|Australia|Bulgaria|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|France|Germany|Hong Kong|Italy|Mexico|Netherlands|New Zealand|Romania|Russian Federation|Slovakia|Spain|Switzerland|Thailand|United Kingdom | 1 |
| Austria|Czechia|Slovakia | 1 |
| Belarus|Poland | 1 |
| Belgium | 1 |
| Belgium|Canada|China|France|Hungary|Italy|Netherlands|Poland|Spain|United Kingdom | 1 |
| Belgium|Denmark|Netherlands | 1 |
| Belgium|France|Germany | 1 |
| Belgium|France|Spain | 1 |
| Belgium|France|United States|Israel|Spain|United Kingdom | 1 |
| Bulgaria|Georgia|Poland | 1 |
| Canada|France | 1 |
| Canada|Germany | 1 |
| Canada|Russian Federation|Spain | 1 |
| China|Malaysia|Australia|Taiwan | 1 |
| China|Philippines|Taiwan|Thailand|Vietnam | 1 |
| Czech Republic | 1 |
| Czechia|Denmark|France|Germany|Hungary|Israel|Italy|United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Korea, Republic of|Netherlands|Poland|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Sweden|Taiwan|Turkey|United Kingdom | 1 |
| Denmark|Netherlands|Spain|United Kingdom | 1 |
| Finland | 1 |
| France|United Kingdom | 1 |
| Germany|Austria|Belgium|Denmark|Finland|Ireland|Israel|Netherlands|Sweden|Switzerland | 1 |
| Germany|Netherlands|United Kingdom | 1 |
| Greece | 1 |
| Hong Kong | 1 |
| India | 1 |
| Ireland | 1 |
| Israel | 1 |
| Japan|Korea, Republic of | 1 |
| Mexico | 1 |
| Poland | 1 |
| Poland|Spain | 1 |
| Poland|United Kingdom | 1 |
| Russian Federation | 1 |
| Spain|Finland|France|Portugal|Sweden|Tunisia|Turkey|United Kingdom | 1 |
| Spain|United States|Australia|Austria|Belgium|Canada|Colombia|Czechia|Denmark|France|Germany|Hungary|Ireland|Israel|Italy|Mexico|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|South Africa|Sweden|United Kingdom | 1 |
| Spain|United States|Australia|Belgium|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|Estonia|France|Germany|Italy|Mexico|New Zealand|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Brazil|Canada | 1 |
| United States|Argentina|Belgium|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|Israel|Korea, Republic of|Mexico|Poland|Portugal|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Croatia|Czechia|Denmark|France|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|South Africa|Spain|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Bulgaria|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Canada|Czechia|France|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Czechia|France|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|France|Ireland|Italy|Poland|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Canada|Chile|Colombia|France|Germany|Hungary|Israel|Italy|Lithuania|New Zealand|Poland|Spain|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Croatia|Czechia|France|Greece|Hungary|Ireland|Italy|Poland|Portugal|Romania|Russian Federation|Spain|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Denmark|France|Hungary|Italy|Netherlands|New Zealand|Norway|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Germany|New Zealand|Sweden|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|China|Czechia|France|Germany|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|France|Germany|Italy|Netherlands|Puerto Rico|United Kingdom | 1 |
| United States|Australia|Brazil|Canada|Denmark|Finland|France|Germany|Italy|Korea, Republic of|Netherlands|Norway|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Brazil|Czech Republic|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Ukraine|United Kingdom | 1 |
| United States|Australia|Canada|France|Germany|Korea, Republic of|Spain|United Kingdom | 1 |
| United States|Australia|Canada|France|Germany|Poland|United Kingdom | 1 |
| United States|Australia|France|Germany|Israel|Korea, Republic of|Spain | 1 |
| United States|Australia|France|Italy|Spain | 1 |
| United States|Australia|Germany|United Kingdom | 1 |
| United States|Australia|Israel|Poland|Ukraine | 1 |
| United States|Australia|Italy|New Zealand|Spain | 1 |
| United States|Australia|New Zealand | 1 |
| United States|Austria | 1 |
| United States|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Netherlands|Norway|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Turkey|United Kingdom | 1 |
| United States|Austria|Bulgaria|Canada|Croatia|France|Germany|Greece|Italy|Poland|Portugal|Romania|Russian Federation|Sweden|Ukraine | 1 |
| United States|Austria|Germany|Italy|Poland|United Kingdom | 1 |
| United States|Austria|Germany|Italy|Spain | 1 |
| United States|Austria|Germany|Poland|Spain | 1 |
| United States|Belgium|Canada|Czechia|Denmark|France|Israel|Netherlands|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom | 1 |
| United States|Belgium|Canada|France|Germany|Israel|Italy|Poland | 1 |
| United States|Belgium|Czech Republic|France|Serbia|United Kingdom | 1 |
| United States|Belgium|Czech Republic|Greece|Italy|Poland|Russian Federation|Spain | 1 |
| United States|Brazil|Bulgaria|Canada|Germany|Greece|India|Italy|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Ukraine|United Kingdom | 1 |
| United States|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom | 1 |
| United States|Canada|France|Netherlands | 1 |
| United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine | 1 |
| United States|Canada|Germany|Italy|Spain|Sweden|United Kingdom | 1 |
| United States|Canada|Puerto Rico|South Africa | 1 |
| United States|Denmark | 1 |
| United States|Denmark|France|United Kingdom | 1 |
| United States|Denmark|Italy | 1 |
| United States|France | 1 |
| United States|France|Germany | 1 |
| United States|France|Germany|Italy|Japan|Netherlands|United Kingdom | 1 |
| United States|France|Germany|Italy|Poland|United Kingdom | 1 |
| United States|France|Germany|Italy|United Kingdom | 1 |
| United States|France|Germany|Spain | 1 |
| United States|Germany|Italy|Spain | 1 |
| United States|Israel | 1 |
| United States|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom | 1 |
| United States|Italy|Poland|United Kingdom | 1 |
| United States|Japan | 1 |
| United States|Poland | 1 |
| United States|Puerto Rico|South Africa | 1 |
| United States|Sweden | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 388 |
| 2 | 71 |
| 3 | 42 |
| 4 | 22 |
| 5 | 26 |
| 6 | 26 |
| 7 | 19 |
| 8 | 10 |
| 9 | 8 |
| 10 | 19 |
| 11 | 24 |
| 12 | 16 |
| 13 | 8 |
| 14 | 5 |
| 15 | 5 |
| 16 | 4 |
| 17 | 6 |
| 18 | 5 |
| 19 | 5 |
| 20 | 5 |
| 21 | 4 |
| 22 | 4 |
| 23 | 7 |
| 24 | 1 |
| 25 | 4 |
| 26 | 3 |
| 27 | 2 |
| 28 | 1 |
| 30 | 2 |
| 31 | 2 |
| 32 | 1 |
| 33 | 3 |
| 34 | 5 |
| 35 | 2 |
| 36 | 1 |
| 38 | 1 |
| 39 | 1 |
| 41 | 2 |
| 44 | 1 |
| 46 | 1 |
| 48 | 4 |
| 50 | 1 |
| 51 | 1 |
| 52 | 1 |
| 53 | 1 |
| 54 | 2 |
| 55 | 1 |
| 57 | 1 |
| 58 | 1 |
| 67 | 1 |
| 69 | 1 |
| 71 | 2 |
| 72 | 1 |
| 75 | 1 |
| 76 | 1 |
| 79 | 1 |
| 80 | 1 |
| 84 | 1 |
| 85 | 1 |
| 86 | 1 |
| 87 | 1 |
| 88 | 1 |
| 91 | 1 |
| 92 | 1 |
| 103 | 1 |
| 106 | 2 |
| 107 | 1 |
| 108 | 2 |
| 111 | 1 |
| 117 | 1 |
| 123 | 1 |
| 125 | 1 |
| 135 | 2 |
| 145 | 2 |
| 150 | 2 |
| 160 | 3 |
| 161 | 1 |
| 162 | 1 |
| 164 | 1 |
| 165 | 1 |
| 174 | 1 |
| 196 | 1 |
| 218 | 1 |
| 241 | 1 |
| 262 | 3 |
| 364 | 1 |
| 747 | 1 |
| 796 | 1 |
| 837 | 1 |
| 954 | 1 |
| Phase | Study_Count |
|---|---|
| Phase 2 | 345 |
| Phase 1 | 236 |
| Phase 1/Phase 2 | 121 |
| Phase 3 | 82 |
| N/A | 23 |
| Early Phase 1 | 11 |
| Phase 4 | 6 |
| Phase 2/Phase 3 | 2 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 488 |
| 2 | 156 |
| 3 | 51 |
| 4 | 27 |
| 5 | 8 |
| 6 | 3 |
| 7 | 3 |
| 8 | 3 |
| 10 | 2 |
| 11 | 1 |
| NA | 84 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 4.00000 | 5.0000 | 2.00000 | 1.00000 | 1.00000 | 11.00 | 20.00 | 10.00000 |
| 1st Qu. | 9.00000 | 28.5000 | 19.25000 | 30.00000 | 28.00000 | 32.25 | 171.75 | 22.25000 |
| Median | 18.00000 | 55.0000 | 33.00000 | 44.00000 | 46.00000 | 53.50 | 318.00 | 30.50000 |
| Mean | 44.54545 | 105.4348 | 51.06838 | 64.63025 | 66.25826 | 53.50 | 401.35 | 87.16667 |
| 3rd Qu. | 31.50000 | 115.0000 | 60.00000 | 80.50000 | 82.00000 | 74.75 | 549.25 | 64.25000 |
| Max. | 312.00000 | 713.0000 | 746.00000 | 403.00000 | 418.00000 | 96.00 | 1337.00 | 357.00000 |
| group_type | Group_Count |
|---|---|
| Experimental | 1052 |
| Active Comparator | 84 |
| NA | 84 |
| Other | 25 |
| No Intervention | 20 |
| Placebo Comparator | 13 |
| Sham Comparator | 1 |
| intervention_model | Study_Count |
|---|---|
| Single Group Assignment | 569 |
| Parallel Assignment | 189 |
| NA | 37 |
| Sequential Assignment | 22 |
| Crossover Assignment | 7 |
| Factorial Assignment | 2 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 783 |
| Supportive Care | 21 |
| Prevention | 10 |
| Basic Science | 6 |
| Other | 3 |
| Diagnostic | 1 |
| Health Services Research | 1 |
| NA | 1 |
| Country | Study_Count |
|---|---|
| United States | 24 |
| France | 8 |
| Italy | 8 |
| Russian Federation | 5 |
| Greece | 3 |
| Korea, Republic of | 3 |
| Argentina | 2 |
| Canada | 2 |
| Israel | 2 |
| NA | 2 |
| Spain | 2 |
| Austria|Germany|Switzerland | 1 |
| Czechia | 1 |
| Finland | 1 |
| Germany | 1 |
| Hungary | 1 |
| India | 1 |
| Ireland|United Kingdom | 1 |
| Italy|Switzerland | 1 |
| Japan | 1 |
| Serbia | 1 |
| Sweden | 1 |
| Switzerland | 1 |
| United Kingdom | 1 |
| United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland | 1 |
| United States|Australia|Canada|Puerto Rico | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 38 |
| 2 | 3 |
| 3 | 3 |
| 4 | 1 |
| 5 | 4 |
| 6 | 2 |
| 8 | 1 |
| 9 | 1 |
| 11 | 1 |
| 13 | 2 |
| 14 | 2 |
| 15 | 2 |
| 16 | 1 |
| 17 | 1 |
| 18 | 1 |
| 25 | 1 |
| 34 | 1 |
| 35 | 1 |
| 39 | 1 |
| 41 | 1 |
| 47 | 1 |
| 55 | 1 |
| 59 | 1 |
| 71 | 1 |
| 84 | 1 |
| 130 | 1 |
| 165 | 1 |
| 192 | 1 |
| Measure | Observational |
|---|---|
| Min | 1.0000 |
| 1st Qu | 66.7500 |
| Median | 145.5000 |
| Mean | 530.6842 |
| 3rd Qu | 437.5000 |
| Max | 4000.0000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 50 |
| Case-Only | 9 |
| Other | 6 |
| Case-Control | 5 |
| Family-Based | 3 |
| NA | 2 |
| Case Control | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 55 |
| Retrospective | 10 |
| Cross-Sectional | 4 |
| Other | 4 |
| NA | 3 |
| Country | Study_Count |
|---|---|
| United States | 4 |
| France | 2 |
| NA | 2 |
| China | 1 |
| Czechia | 1 |
| Turkey | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 7 |
| 2 | 2 |
| 11 | 1 |
| 192 | 1 |
| Measure | Registries |
|---|---|
| Min | 198.000 |
| 1st Qu | 328.000 |
| Median | 1000.000 |
| Mean | 2193.909 |
| 3rd Qu | 2897.500 |
| Max | 10000.000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 9 |
| Other | 2 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 9 |
| Cross-Sectional | 1 |
| Other | 1 |
| target_duration | Study_Count |
|---|---|
| 10 Years | 4 |
| 2 Years | 3 |
| 1 Year | 1 |
| 12 Months | 1 |
| 3 Years | 1 |
| 5 Years | 1 |
#If less then 500 trials
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03375619 | Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells | https://ClinicalTrials.gov/show/NCT03375619 | Recruiting | Medical College of Wisconsin | 2020-08-01 |
| NCT03374137 | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT03374137 | Recruiting | Hoffmann-La Roche | 2020-09-30 |
| NCT03582098 | Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | https://ClinicalTrials.gov/show/NCT03582098 | Completed | Gilead Sciences | 2019-03-26 |
| NCT03342144 | Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | https://ClinicalTrials.gov/show/NCT03342144 | Recruiting | AbbVie | 2022-12-31 |
| NCT03316209 | Identification of Occupational Exposures in Acute Hematologic Malignancy | https://ClinicalTrials.gov/show/NCT03316209 | Recruiting | Centre Hospitalier Intercommunal Creteil | 2020-03-31 |
| NCT03294980 | Chronic Lymphoid Leukaemia Observatory in Finistere Area, France | https://ClinicalTrials.gov/show/NCT03294980 | Recruiting | University Hospital, Brest | 2025-11-30 |
| NCT03289182 | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin’s Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) | https://ClinicalTrials.gov/show/NCT03289182 | Active, not recruiting | Hoffmann-La Roche | 2020-10-26 |
| NCT03231579 | Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study | https://ClinicalTrials.gov/show/NCT03231579 | Completed | Carevive Systems, Inc. | 2018-11-01 |
| NCT03059251 | Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | https://ClinicalTrials.gov/show/NCT03059251 | Completed | Hoffmann-La Roche | 2019-03-30 |
| NCT02915224 | A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities | https://ClinicalTrials.gov/show/NCT02915224 | Active, not recruiting | Hoffmann-La Roche | 2020-04-30 |
| NCT02842229 | A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms | https://ClinicalTrials.gov/show/NCT02842229 | Completed | Celgene | 2017-02-02 |
| NCT02827617 | Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02827617 | Recruiting | Oncology Institute of Southern Switzerland | 2021-02-28 |
| NCT02767388 | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery | https://ClinicalTrials.gov/show/NCT02767388 | Completed | University of Nebraska | 2017-12-11 |
| NCT02582320 | Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program | https://ClinicalTrials.gov/show/NCT02582320 | Recruiting | Gruppo Italiano Malattie EMatologiche dell’Adulto | 2018-12-31 |
| NCT01087333 | Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | https://ClinicalTrials.gov/show/NCT01087333 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT00131014 | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | https://ClinicalTrials.gov/show/NCT00131014 | Recruiting | Dana-Farber Cancer Institute | 2023-01-31 |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | https://ClinicalTrials.gov/show/NCT00039676 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT02520895 | Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02520895 | Completed | Hospices Civils de Lyon | 2013-10-31 |
| NCT02491398 | Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia | https://ClinicalTrials.gov/show/NCT02491398 | Active, not recruiting | Gruppo Italiano Malattie EMatologiche dell’Adulto | 2018-10-31 |
| NCT02461316 | Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02461316 | Completed | Hoffmann-La Roche | 2011-12-31 |
| NCT02414022 | Economic Analysis of Alliance A041202 CLL Study | https://ClinicalTrials.gov/show/NCT02414022 | Active, not recruiting | Canadian Cancer Trials Group | 2019-04-05 |
| NCT02381899 | Observational Study in CLL Patients Receiving BR | https://ClinicalTrials.gov/show/NCT02381899 | Completed | Czech CLL Study Group | 2016-12-31 |
| NCT02269592 | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | https://ClinicalTrials.gov/show/NCT02269592 | Recruiting | Dana-Farber Cancer Institute | 2024-12-31 |
| NCT02110394 | Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02110394 | Completed | Astellas Pharma Inc | 2015-08-31 |
| NCT02080884 | An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02080884 | Completed | Hoffmann-La Roche | 2016-12-19 |
| NCT02057185 | Occupational Status and Hematological Disease | https://ClinicalTrials.gov/show/NCT02057185 | Active, not recruiting | Gruppo Italiano Malattie EMatologiche dell’Adulto | 2019-03-31 |
| NCT03310190 | Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT03310190 | Recruiting | AbbVie | 2021-06-30 |
| NCT01832597 | Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders | https://ClinicalTrials.gov/show/NCT01832597 | Completed | Gruppo Italiano Studio Linfomi | 2010-12-31 |
| NCT01609023 | A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01609023 | Completed | Hoffmann-La Roche | 2015-11-30 |
| NCT01488162 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01488162 | Completed | Hoffmann-La Roche | 2016-10-24 |
| NCT01460238 | Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01460238 | Completed | Dartmouth-Hitchcock Medical Center | 2018-05-31 |
| NCT01453062 | Phase IV Observational Study in Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01453062 | Completed | GlaxoSmithKline | 2012-11-30 |
| NCT01397916 | Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) | https://ClinicalTrials.gov/show/NCT01397916 | Completed | Tampere University Hospital | 2010-12-31 |
| NCT01395615 | An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia | https://ClinicalTrials.gov/show/NCT01395615 | Completed | Hoffmann-La Roche | 2009-10-31 |
| NCT04407845 | Atrial Fibrillation in Patients Receiving Ibrutinib | https://ClinicalTrials.gov/show/NCT04407845 | Recruiting | European Georges Pompidou Hospital | 2022-05-21 |
| NCT04290923 | Determination of Blood Tumor Cells | https://ClinicalTrials.gov/show/NCT04290923 | Recruiting | University of Zurich | 2020-09-30 |
| NCT04198415 | A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) | https://ClinicalTrials.gov/show/NCT04198415 | Recruiting | AbbVie | 2022-03-31 |
| NCT04178317 | A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT04178317 | Recruiting | AbbVie | 2026-03-25 |
| NCT04159779 | A Study of Clinical Outcomes in Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | https://ClinicalTrials.gov/show/NCT04159779 | Recruiting | AbbVie | 2020-11-25 |
| NCT04028531 | Understanding Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT04028531 | Recruiting | Dana-Farber Cancer Institute | 2024-09-29 |
| NCT04016636 | A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT04016636 | Recruiting | Fundaleu | 2021-08-31 |
| NCT03971565 | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT03971565 | Recruiting | Assistance Publique Hopitaux De Marseille | 2021-03-18 |
| NCT03873857 | A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation | https://ClinicalTrials.gov/show/NCT03873857 | Recruiting | AbbVie | 2022-12-03 |
| NCT03847727 | Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT03847727 | Active, not recruiting | Pirogov Russian National Research Medical University | 2019-12-03 |
| NCT03720561 | A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting | https://ClinicalTrials.gov/show/NCT03720561 | Active, not recruiting | Janssen-Cilag S.p.A. | 2021-10-31 |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT03659669 | Recruiting | AbbVie | 2024-10-31 |
| NCT03633045 | Observational Study of Ibrutinib Use in CLL | https://ClinicalTrials.gov/show/NCT03633045 | Recruiting | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | 2021-09-30 |
| NCT03529227 | Gazyva Infusion Reaction Investigation | https://ClinicalTrials.gov/show/NCT03529227 | Recruiting | Healthy Future | 2019-03-31 |
| NCT03528941 | The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib | https://ClinicalTrials.gov/show/NCT03528941 | Recruiting | Gruppo Italiano Malattie EMatologiche dell’Adulto | 2020-08-31 |
| NCT03476655 | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | https://ClinicalTrials.gov/show/NCT03476655 | Completed | Johnson & Johnson Private Limited | 2019-05-14 |
| NCT03436524 | A Prognostic Tool for Early Stage CLL | https://ClinicalTrials.gov/show/NCT03436524 | Recruiting | Oncology Institute of Southern Switzerland | 2020-02-28 |
| NCT03425591 | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT03425591 | Recruiting | Janssen-Cilag Ltd. | 2022-05-22 |
| NCT03415035 | Study Venetoclax Effectiveness and Realâ€Life Treatment Management in Participants With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT03415035 | Recruiting | AbbVie | 2022-03-30 |
| NCT01224093 | An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) | https://ClinicalTrials.gov/show/NCT01224093 | Completed | Hoffmann-La Roche | 2014-02-28 |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | https://ClinicalTrials.gov/show/NCT01199562 | Completed | City of Hope Medical Center | 2013-12-31 |
| NCT01178086 | A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | https://ClinicalTrials.gov/show/NCT01178086 | Completed | Hoffmann-La Roche | 2015-06-30 |
| NCT01145469 | Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy | https://ClinicalTrials.gov/show/NCT01145469 | Completed | Eastern Cooperative Oncology Group | 2010-08-01 |
| NCT01117142 | A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers | https://ClinicalTrials.gov/show/NCT01117142 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT01110863 | Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects | https://ClinicalTrials.gov/show/NCT01110863 | Completed | Northwell Health | 2016-02-12 |
| NCT01110850 | Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water | https://ClinicalTrials.gov/show/NCT01110850 | Completed | Northwell Health | 2018-05-31 |
| NCT01081015 | Connectâ„¢ CLL: The Chronic Lymphocytic Leukemia Disease Registry | https://ClinicalTrials.gov/show/NCT01081015 | Completed | Celgene | 2017-12-31 |
| NCT01072240 | An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01072240 | Completed | Hoffmann-La Roche | 2011-06-30 |
| NCT01030913 | B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression | https://ClinicalTrials.gov/show/NCT01030913 | Recruiting | Northwell Health | 2021-01-31 |
| NCT01028430 | B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging | https://ClinicalTrials.gov/show/NCT01028430 | Recruiting | Northwell Health | 2021-01-31 |
| NCT01005368 | Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT01005368 | Active, not recruiting | Alliance for Clinical Trials in Oncology | 2100-01-31 |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT01000753 | Active, not recruiting | Children’s Oncology Group | 2007-06-01 |
| NCT00923507 | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | https://ClinicalTrials.gov/show/NCT00923507 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT00898079 | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | https://ClinicalTrials.gov/show/NCT00898079 | Completed | Children’s Oncology Group | 2018-06-30 |
| NCT00889031 | Protocol to Obtain Blood Samples for Leukemia Research | https://ClinicalTrials.gov/show/NCT00889031 | Completed | Dartmouth-Hitchcock Medical Center | 2018-03-09 |
| NCT00626496 | Family Study of Lymphoproliferative Disorders | https://ClinicalTrials.gov/show/NCT00626496 | Recruiting | Mayo Clinic | 2025-12-31 |
| NCT00569842 | Investigation of the Cylex® ImmuKnow® Assay | https://ClinicalTrials.gov/show/NCT00569842 | Completed | Indiana University | 2010-02-28 |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | https://ClinicalTrials.gov/show/NCT00513175 | Completed | University of California, San Francisco | NA |
| NCT00503256 | Genetic Study of Chronic Lymphocytic Leukemia Families | https://ClinicalTrials.gov/show/NCT00503256 | Active, not recruiting | M.D. Anderson Cancer Center | 2019-09-30 |
| NCT00481858 | Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis | https://ClinicalTrials.gov/show/NCT00481858 | Completed | KineMed | 2010-07-31 |
| NCT00344825 | Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL) | https://ClinicalTrials.gov/show/NCT00344825 | Completed | Sanofi | 2006-11-30 |
| NCT00159003 | Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel | https://ClinicalTrials.gov/show/NCT00159003 | Completed | Hadassah Medical Organization | 2017-07-01 |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | https://ClinicalTrials.gov/show/NCT04342117 | Recruiting | Verastem, Inc. | 2023-04-30 |
| NCT03197259 | Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study | https://ClinicalTrials.gov/show/NCT03197259 | Recruiting | Izmir Hematologic Diseases and Cancer Research Help Association | 2020-01-01 |
| NCT02869529 | Institut Paoli Calmettes Chronic Lymphatic Leukemia Database | https://ClinicalTrials.gov/show/NCT02869529 | Recruiting | Institut Paoli-Calmettes | 2030-01-31 |
| NCT02582879 | informCLLâ„¢: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | https://ClinicalTrials.gov/show/NCT02582879 | Active, not recruiting | Pharmacyclics LLC. | 2021-10-31 |
| NCT02553304 | Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients | https://ClinicalTrials.gov/show/NCT02553304 | Active, not recruiting | National Health Research Institutes, Taiwan | 2019-01-25 |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry | https://ClinicalTrials.gov/show/NCT02298816 | Enrolling by invitation | Aurora Health Care | 2024-12-31 |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | https://ClinicalTrials.gov/show/NCT01890486 | Recruiting | Wake Forest University Health Sciences | 2023-05-31 |
| NCT04094051 | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT04094051 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 2020-12-31 |
| NCT03881592 | Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness | https://ClinicalTrials.gov/show/NCT03881592 | Recruiting | Brno University Hospital | 2019-06-30 |
| NCT03502876 | Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL | https://ClinicalTrials.gov/show/NCT03502876 | Completed | French Innovative Leukemia Organisation | 2018-12-31 |
| NCT00889798 | Tumor Registry of Lymphatic Neoplasia | https://ClinicalTrials.gov/show/NCT00889798 | Completed | iOMEDICO AG | 2019-08-31 |